Abstract 47P
Background
In CRC molecular studies have shown that there is a great inter-tumour heterogeneity (ITH) within each UICC TNM stage and therefore a range of other transcriptional and protein biomarkers need to be investigated independently of the UICC TNM staging. In CRC, one of these adverse prognostic factors is tumour budding, Typically, tumour budding is assessed using H&E-stained specimens but scoring methods and grading schemes vary widely. A retrospective study was carried out to study the differential expression of discriminative markers in matched invasion fronts and tumour buds of 44 patients with stage 3/4 CRC disease.
Methods
A retrospective study was done on 44 Formalin Fixed paraffin embedded tissue sections with at least stage 3/4 CRC disease. These cases were used to study the expression differences between the central portion of the tumour, the invasion front and the tumour buds using the Luminex bead-based assay. The different tumoral compartments were assessed by a pathologist on a H&E stained slide and a 0.5mm core was obtained from each respective area on the specimen block. The core was lysed for 18 – 22 hrs at 58°C. After overnight incubation, hybridization-based assay was performed to study the expression of 50 different genes. Data analysis was carried out to see if there is any statistically significant difference between the central portion of the tumour, the invasion front and tumour buds.
Results
A statistically significant differences was noted in the expression of TRIB1 and CCND3 when comparing the central portion of the tumour to the tumour buds. The expression of TRIB1 and CCND3was higher in the buds than that of the central tumour. A statistically significant difference was seen in the expression of CDX2 when comparing the invasion front to the tumour bud. CDX2 was higher in the invasion front than in the tumour buds. A statistically significant difference was also seen in the expression of MCL1 which was higher in the invasion fronts when compared to the central tumour part.
Conclusions
With the use of a bead based multiplex assay we were able to carry out differential expression of a number of genes related to invasiveness, metastasis and treatment resistance in matched central tumour, invasion fronts and tumour buds in CRC patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Emanuele Cancer Research Foundation Malta.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract